Aiming to determine whether EZH2 inhibition could restore HDAC7 expression, we selected two EZH2 inhibitors (GSK126 and EPZ6438) and exposed t(4;11) pro-B-ALL cells to increasing doses of these drugs. Here, HDAC7 is linked to acute lymphoblastic leukemia.